InterCure Ltd.

Tel Aviv Stock Exchange INCR.TA

InterCure Ltd. Capital Expenditure for the year ending December 31, 2023: USD -721.30 K

InterCure Ltd. Capital Expenditure is USD -721.30 K for the year ending December 31, 2023, a 87.14% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

InterCure Ltd. Capital Expenditure for the year ending December 31, 2022 was USD -5.61 M, a -24.26% change year over year.
InterCure Ltd. Capital Expenditure for the year ending December 31, 2021 was USD -4.51 M, a 30.35% change year over year.
InterCure Ltd. Capital Expenditure for the year ending December 31, 2020 was USD -6.48 M, a -2,242,485.05% change year over year.
InterCure Ltd. Capital Expenditure for the year ending December 31, 2019 was USD -289.04, a 98.84% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Tel Aviv Stock Exchange: INCR.TA

InterCure Ltd.

CEO	Mr. Alexander Rabinovich
IPO Date	Sept. 9, 2007
Location	Israel
Headquarters	85 Medinat ha-Yehudim Street
Employees	270
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.

Key trends

Past 5 years